吉法匹生片的副作用与注意事项

Gefapixant is the world's first selective P2X3 receptor antagonist, providing an innovative treatment option for patients with refractory chronic cough. This drug, jointly developed by Merck & Co. of the United States and Japan's Kyorin Pharmaceuticals, affects the airway vagus nerve through a unique mechanism, but its use is also accompanied by specific adverse reactions and precautions.

Side effects of Gemfapixin tablets

While exerting its antitussive effect, it may cause a variety of adverse reactions. These reactions are mainly related to the selective inhibition of P2X3 receptors by the drug.

Taste-related disorders

Abnormal taste is the most significant characteristic side effect of this drug, which manifests as hypogeusia, loss of taste or distortion of taste. Clinical data shows that these symptoms are more obvious in the early stages of medication, and most patients can gradually adapt after continuing to take medication for several weeks.

Digestive system reactions

Gastrointestinal symptoms such as nausea and dry mouth are relatively common. Some patients may experience upper abdominal discomfort or loss of appetite. These symptoms are usually mild to moderate and can be alleviated by adjusting the administration method.

Other systemic reactions

A few patients report dizziness or upper respiratory tract infection symptoms, and a small number of patients may have a paradoxical phenomenon of worsening cough, which needs to be distinguished from the progression of the underlying disease.

Understanding the characteristics of these side effects can help clinicians identify and intervene early and improve patient medication compliance.

Precautions for Gefapisheng Tablets

Rational use of Gefapisheng Tablets requires attention to many key aspects. The following matters need to be paid attention to when using the drug.

Usage for special groups

It is contraindicated in patients with severe liver dysfunction. Patients with renal impairment need to adjust the dose based on eGFR, and patients with severe renal impairment should reduce the dose to once a day. Elderly patients should have their kidney function monitored regularly.

Drug monitoring requirements

During treatment, changes in cough symptoms need to be regularly evaluated, and taste function and renal function indicators need to be monitored at the same time. Dosage adjustment should be considered in the presence of persistent dysgeusia.

Drug Interactions

Although Gemfapixin tablets are not metabolized by CYP enzymes, caution is still required when used in combination with drugs that are excreted by the kidneys. Concomitant use with strong P-gp inhibitors should be avoided.

Following these precautions can optimize treatment effects and minimize medication risks.

The efficacy of Gefapisheng Tablets

Gefapisheng Tablets have shown unique clinical value in the treatment of refractory chronic cough, and its efficacy characteristics deserve in-depth discussion.

Innovative mechanism of action

As the first P2X3 receptor antagonist, it effectively inhibits ATP-mediated excessive activation of the cough reflex by selectively blocking the P2X3 receptor of the airway vagus nerve, filling the gap in the symptomatic treatment of chronic cough.

Clinical efficacy data

Phase III clinical trials show that a dose of 45 mg twice a day can significantly reduce the frequency of coughing and significantly improve the patient's quality of life. The efficacy usually appears after a few weeks of medication.

Benefits of long-term treatment

Continuous use of the drug can maintain a stable antitussive effect without causing tolerance, and it has shown good symptom control effects on refractory chronic cough caused by a variety of causes.

These therapeutic characteristics of Gemfapixin Tablets provide a new treatment option for patients with refractory chronic cough, and its clinical application prospects are broad.